[Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: Vasoactive mechanisms and inotropic action in disease

Hypertension

Volumn 54, Issue 3, 2009, Pages 598-604

  Maguire, Janet J ^a   Kleinz, Matthias J ^a   Pitkin, Sarah L ^a   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apelin; Human apelin receptor APJ; Positive cardiac inotropic agents; Vasoconstriction; Vasodilatation

Indexed keywords

APELIN; APELIN 13; APELIN 13 PYR 1; APELIN 36; APELIN RECEPTOR; INDOMETACIN; N(G) NITRO DEXTRO ARGININE METHYL ESTER; NEUROPEPTIDE; NITRIC OXIDE; PROSTANOID; UNCLASSIFIED DRUG; APELIN 13 PEPTIDE; APELIN-13 PEPTIDE; APLN PROTEIN, HUMAN; CARDIOTONIC AGENT; ISOPROTEIN; SIGNAL PEPTIDE;

ARTICLE; AUTOCRINE EFFECT; BLOOD; BLOOD VESSEL; CELL CULTURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG POTENCY; ENDOTHELIUM CELL; HEART; HEART CONTRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; INCUBATION TIME; INOTROPISM; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; SAPHENOUS VEIN; VASOCONSTRICTION; VASODILATATION; AGED; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAMMARY ARTERY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIOIMMUNOASSAY; VASCULAR ENDOTHELIUM;

AGED; CARDIOTONIC AGENTS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAMMARY ARTERIES; MYOCARDIUM; PROTEIN ISOFORMS; RADIOIMMUNOASSAY; SAPHENOUS VEIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; VASODILATION;

EID: 70349245019     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.134619     Document Type: Article

References (46)

1. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome. Gene. 1993;136:355-360.
2. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-476.
3. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, Fujino M. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta. 1999;1452: 25-35.
4. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41.
5. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, Corvol P, Palkovits M, Llorens-Cortes C. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem. 2001;77:1085-1096.
6. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107:198-211.
7. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, Kolson DL, Mitrovic B, Zhou Y, Faulds D, Collman RG, Hesselgesser J, Horuk R, Doms RW. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 1998; 72:7934-7940.
8. Zhou N, Fan X, Mukhtar M, Fang J, Patel CA, DuBois GC, Pomerantz RJ. Cell-cell fusion and internalization of the CNS-based, HIV-1 co-receptor, APJ. Virology. 2003;307:22-36.
9. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favours messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148:2690-2697.
10. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpéné C, Audigier Y, Saulnier-Blache J-S, Valet P. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146: 1764-1771.
11. Sörhede M, Magnusson C, Ahrén B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regulat Pept. 2005;131:12-17.
12. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben-Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation. 2003;108:1432-1439.
13. Miettinen KH, Magga J, Vuolteenaho O, Vanninen EJ, Punnonen Kr, Ylitalo K, Tuomainen P, Peuhkurinen KJ. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Reg Peptides. 2007;140:178-184.
14. Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mayranpaa M, Sarman B, Seres L, Skoumal R, Lako-Futo Z, deChatel R, Ruskoaho H, Toth M. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun. 2003;308:480-485.
15. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8:355-360.
16. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118:119-125.
17. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005;126:233-240.
18. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J. 2004;18:1909-1911.
19. Japp AG, Cruden NL, Amer DA, Li VKY, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52: 908-913.
20. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92.
21. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N, Fukamizu A. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279:26274-26279.
22. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]- (Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol. 2001;132:1255-1260.
23. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65:73-82.
24. Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, Woo YJ. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation. 2004;110:II187-II193.
25. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-440.
26. Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept. 2006;133:147-154.
27. Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;470:171-175.
28. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;553:222-228.
29. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Liebbrandt A, Makovic M, Scwaighofer J, Beetz N, Musialek R, Neely G, Komnenovic V, Kolm U, Metzler B, Ricci R, Hara H, Meixner A, Nghiem M, Chen X,Dawood F, Wong KM, Sarao R, Cukerman E, Kimura A, Hein L, Thalhammer J, Liu PP, Penninger JM. Impaired heart Contractility in apelin gene deficient mice associated with aging and pressure overload. Circ Res. 2007;101:e32-e42.
30. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M. Molecular and functional characteristics of APJ: tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275:21061-21067.
31. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, Kitada C, Onda H, Nishimura O, Fujino M. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538:162-171.
32. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-1172.
33. Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N, Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J. Apelin, the natural ligand of the orphan seventransmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol. 2000;74:11972-11976.
34. Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett. 2000;473:15-18.
35. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146:231-236.
36. Salcedo A, Garijo J, Monge L, Fernández N, García- Villalón AL, Turrión VS, Cuervas-Mons V, Diéguez G. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept. 2007;44:50-55.
37. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida SI, Toya Y, Fukamizu A, Kitamura H, Umemura S. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2006;26:1267-1272.
38. Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, Marczin N, Szokodi I, Yacoub MH, Terracciano CMN. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun. 2007;357:889-895.
39. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
40. Davenport AP, Nunez DJ, Hall JA, Kaumann AJ, Brown MJ. Autoradiographical localization of binding sites for [125I]endothelin-1 in humans, pig, and rats; functional relevance in humans. J Cardiovasc Pharmacol. 1989;13(suppl 5):S166-S170.
41. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A. 2004;101:10464-10469.
42. Maguire JJ, Davenport AP. Regulation of vascular reactivity by established and emerging GPCRs. Trends Pharmacol Sci. 2005;26:448-454.
43. Jaszberenyi M, Bujdoso E, Telegdy G. Behavioral, neuroendocrine and thermoregulatory actions of apelin-13. Neuroscience. 2004;129:811-816.
44. Kelly RA, Eid H, Kramer BK, O'Neill M, Liang BT, Reers M, Smith TW. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest. 1990;86:1164-1171.
45. Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998;97: 1062-1070.
46. Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol. 2001;132:5-9.